Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2351
MediaAlpha
MAX
$807M
| $1.33M | ﹤0.01% |
134,000
+89,300
| +200% | +$984K |
|
|
ME
2352
DELISTED
23andMe Holding Co
ME
| $1.33M | ﹤0.01% |
30,845
-29,520
| -49% | -$1.72M |
|
|
LITB
2353
LightInTheBox
LITB
$60.7M
| $1.33M | ﹤0.01% |
180,389
-15,506
| -8% | -$102K |
|
2354
Live Ventures
LIVE
$32M
| $1.33M | ﹤0.01% |
42,499
-4,000
| -9% | -$101K |
|
2355
Madrigal Pharmaceuticals
MDGL
$11.7B
| $1.33M | ﹤0.01% |
+4,582
| New | +$448K |
|
2356
Hurco Companies Inc
HURC
$146M
| $1.33M | ﹤0.01% |
50,806
-7,291
| -13% | -$181K |
|
2357
Principal Financial Group
PFG
$24.4B
| $1.33M | ﹤0.01% |
+15,822
| New | +$1.36M |
|
2358
Sensus Healthcare
SRTS
$47.1M
| $1.33M | ﹤0.01% |
178,734
-87,300
| -33% | -$787K |
|
2359
Scholar Rock
SRRK
$6.4B
| $1.32M | ﹤0.01% |
146,400
+69,000
| +89% | +$553K |
|
2360
ARKO Corp
ARKO
$544M
| $1.32M | ﹤0.01% |
152,900
+46,500
| +44% | +$431K |
|
2361
HUTCHMED
HCM
$2.12B
| $1.32M | ﹤0.01% |
89,552
-2,400
| -3% | -$26.2K |
|
2362
PAR Technology
PAR
$788M
| $1.32M | ﹤0.01% |
50,800
+18,033
| +55% | +$464K |
|
2363
Universal Insurance Holdings
UVE
$1.2B
| $1.32M | ﹤0.01% |
+125,000
| New | +$1.27M |
|
2364
Viemed Healthcare
VMD
$350M
| $1.32M | ﹤0.01% |
175,100
-89,300
| -34% | -$605K |
|
|
RTC
2365
DELISTED
Baijiayun Group
RTC
| $1.32M | ﹤0.01% |
28,179
-3,060
| -10% | -$119K |
|
2366
Immersion
IMMR
$249M
| $1.32M | ﹤0.01% |
187,300
-229,713
| -55% | -$1.48M |
|
2367
Peoples Financial Services
PFIS
$714M
| $1.32M | ﹤0.01% |
25,381
-2,774
| -10% | -$148K |
|
2368
Global Net Lease
GNL
$2.03B
| $1.31M | ﹤0.01% |
104,600
+27,000
| +35% | +$335K |
|
2369
Vanguard Consumer Discretionary ETF
VCR
$6.11B
| $1.31M | ﹤0.01% |
+6,000
| New | +$1.41M |
|
2370
Cumberland Pharmaceuticals
CPIX
$117M
| $1.31M | ﹤0.01% |
581,963
-14,900
| -2% | -$34.6K |
|
2371
Hooker Furnishings Corp
HOFT
$158M
| $1.3M | ﹤0.01% |
69,700
-10,765
| -13% | -$174K |
|
2372
Nurix Therapeutics
NRIX
$2.81B
| $1.3M | ﹤0.01% |
118,700
+45,400
| +62% | +$548K |
|
|
GHG
2373
GreenTree Hospitality
GHG
$112M
| $1.3M | ﹤0.01% |
350,804
-28,700
| -8% | -$87.9K |
|
2374
Goldman Sachs ActiveBeta Emerging Markets Equity ETF
GEM
$1.74B
| $1.3M | ﹤0.01% |
45,800
+22,700
| +98% | +$622K |
|
2375
Lennar Class B
LEN.B
$20.6B
| $1.29M | ﹤0.01% |
18,200
-28,248
| -61% | -$1.83M |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 522 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 522 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.